Deep Track Capital’s MiNK Therapeutics INKT Stock Holding History

Deep Track Capital’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-32,487	Closed	-$682K	–	67
2023 Q2	$682K	Buy	+32,487	New	+$651K	0.03%	55

Other funds holding INKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deep Track Capital's INKT Position: Q3 2023 in Review

Deep Track Capital sold out of MiNK Therapeutics (INKT) in Q3 2023, closing a stake of 32,487 shares — an estimated $682K sold.

Deep Track Capital first reported a position in INKT in Q2 2023 and held it in 1 quarter. The position peaked at $682K in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q3 2023.

Deep Track Capital reported no remaining MiNK Therapeutics position as of Q3 2023 after selling out during the quarter.
Deep Track Capital sold 32,487 MiNK Therapeutics shares in Q3 2023, an estimated $682K.
Deep Track Capital first reported a position in MiNK Therapeutics in Q2 2023 and held it in 1 quarter.
Deep Track Capital's MiNK Therapeutics position peaked at $682K in Q2 2023.
34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2023.

Based on Deep Track Capital's 13F filing for Q3 2023, filed 14 Nov 2023.